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Abstract
A simple high‐performance liquid chromatography method for the determination of
hydromorphone in small volume plasma has been developed. Following solid‐phase
extraction using Oasis HLB cartridges, samples were separated by reverse‐phase
high‐performance liquid chromatography on an Atlantis T3 4.6 × 150 mm column
(3.0 μm) and quantified using mass spectrometry. The mobile phase was a mixture
of water with 0.1% formic acid and acetonitrile with 0.1% formic acid (91:9). The standard curve ranged from 1 to 500 ng/mL. Intra‐ and Inter‐assay variability for
hydromorphone was <10%, and the average recovery was >90%. The LLOQ was
1 ng/mL. This method was successfully applied to the analysis of hydromorphone
samples at this institution. This method could be useful to those investigators dealing
with small sample volumes, particularly when conducting pharmacokinetic studies
that require multiple sampling from the same animal.
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I N T RO D U CT I O N

Despite the rising popularity of hydromorphone in reptile medicine in the USA, reptile formularies do not contain dosing recommen-

Recognition of pain and appropriate analgesic therapy is becoming

dations for analgesic regimens in reptiles. Doses are often adjusted

increasingly important in veterinary medicine. Opioids are a diverse

based on pharmacokinetic and pharmacodynamics principles known

group of drugs that bind to specific receptors in the brain, spinal

from domestic animals (Sladky, Mader, & Divers, 2014). Pharmacoki-

cord, and peripheral tissues. They are used for their analgesic prop-

netic data from studies indicate a large degree of variation between

erties, acting on the μ‐, κ‐ and δ‐opioid receptors in the central

species. The half‐life in cats, macaques, kestrels and dogs is 98.9,

nervous system and peripheral nervous system (Lamount &

142, 75 and 60 min, respectively (Wegner, Robertson, Kollias‐Baker,

Mathews, 2007). Hydromorphone is a semi‐synthetic μ‐opioid

Sams & Muir, 2004; KuKanich, Hogan, Krugner‐Higby & Smith,

receptor agonist with a potency 5–7 times that of morphine

2008; Kelly, Pypendop & Christe, 2014; Guzman Sanchez‐Migallon,

(Murray & Hagen, 2005). Extensive research studies support the

KuKanich, Drazenovich, Olsen & Paul‐Murphy, 2014). Clearance is

clinical use of hydromorphone in pain management protocols (Kelly,

24.6, 37.7, 62.3 and 60 mL/min/kg in cats, macaques, kestrels and

Pypendop, & Christe, 2014). It is used frequently in the USA in

dogs. (Guzman Sanchez‐Migallon et al., 2014; Kelly et al., 2014;

small animal anesthesia and for pain management because of its

KuKanich et al., 2008; Wegner et al., 2004), while the volume of dis-

low cost and apparent good efficacy and safety history (Pettifer &

tribution at steady state is 2957, 4062, 1164 and 4410 mL/kg and the

Dyson, 2000). In addition to use in mammals, hydromorphone anal-

area under the curve is 4079, 1993, 3508 and 7350 mL/min/kg in

gesic efficacy has been validated in red‐eared slider turtles (Mans,

cats, macaques, kestrels and dogs, respectively (Guzman Sanchez‐

Lahner, Baker, Johnson, & Sladky, 2012). It is also an accepted

Migallon et al., 2014; Kelly et al., 2014; KuKanich et al., 2008;

alternative to morphine because it does not cause histamine release

Wegner et al., 2004). The lack of pharmacokinetic data for analgesic

after i.v. administration (Pettifer & Dyson, 2000; Smith, Yu, Bjorling,

agents in reptiles makes it impossible to determine appropriate doses,

& Waller, 2001).

dosing intervals and safety, hampering the appropriate selection and
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use of analgesics in clinical practice. As such, it is difficult to recom-
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mend effective and safe dosing intervals for reptiles. Owing to the
large degree of variation in metabolism, pharmacokinetic parameters

2.1

|

Chemicals and standards

must be established for each species.
There have been some methods reported for the determination of

Hydromorphone and naltrexone (Figure 1) were purchased from US

hydromorphone in human plasma which involved radioimmunoassay

Pharmacopeia (Rockville, MD, USA). Both chemicals were >99%

(Lee et al., 1991), high‐performance liquid chromatography using elec-

purity. All other mass spectrometry grade chemicals and solvents were

trochemical detection (Wetzelsberger, Lucker, & Erking, 1986;

purchased from Fisher Scientific (Pittsburg, PA, USA).

Bouquilion, Freeman, & Moulin, 1992; Guedes, Papich, Rude & Rider,

Stock solutions of hydromorphone (100 μg/mL) and naltrexone

2008) and high‐performance liquid chromatography tandem mass

(100 μg/mL), which is the internal standard, were prepared in metha-

spectrometry (MS) (Chen, Hanson, Jiang, & Naidong, 2002; Coles,

nol. Dilutions in methanol were prepared to produce 0.01, 0.1 and

Kushnir, Nelson, McMillin, & Urry, 2007; Dahn, Gunn, Kriger, & Terrell,

1 μg/mL working stocks. Solutions were aliquoted into separate vials

2010; Kelly et al., 2014; KuKanich et al., 2008; Musshoff, Trafkowski,

to prevent evaporation and cross‐contamination. All solutions were

Kuepper, & Madea, 2006; Naidong et al., 2000; Wegner et al., 2004).

stored at 4°C. By comparing standard areas over time it was deter-

The radioimmunoassay method (Lee et al., 1991) lacks selectivity and

mined that they were stable for a minimum of 6 months.

requires the use of radioactivity, which requires a license and can be

For preparation of calibration standards and quality control sam-

costly to dispose of, and a large volume of plasma. The electrochemi-

ples, appropriate aliquots of the working stock solutions were placed

cal detection methods require large sample volumes, have poor recov-

in tubes, evaporated to dryness with nitrogen and then dissolved in

ery and are not as sensitive (Wetzelsberger et al., 1986, Bouquilion

100 μL of untreated lithium heparin bearded dragon plasma. The

et al., 1992, Guedes et al., 2008).

plasma was obtained from drug‐free healthy animals. The final con-

Many of the LC‐MS methods use large sample sizes and have

centrations were 1, 2.5, 5, 10, 25, 50, 100, 250 and 500 ng/mL for cal-

more complex time‐consuming extractions. The methods used in

ibration standards and 3.5, 15, 35, 75, 150 and 350 μg/mL for quality

the studies by Kelly et al. (2014) and KuKanich et al. (2008)

control samples. Calibration standards and control samples were

required larger sample sizes (0.5 and 1 mL) and were not as accu-

treated identically to samples. Linearity was assessed by linear regres-

rate or precise. The method used by Kelly et al. (2014) does have

sion analysis. The calibration curve had a correlation coefficient of

a lower LOQ (0.1 ng/mL) but they used a triple quadrupole detector

≥0.99. The acceptance criterion for each back‐calculated standard

and a larger sample size to obtain the value. One method (Chen

and quality control concentration was 15% deviation from the nominal

et al., 2002) requires the use of a robotic liquid handler which is

value except for the lower limit of quantification (LLOQ), which was

costly and may not be available in many laboratories. It also has

set at 20%.

poor recovery while another method (Musshoff et al., 2006)
requires cannula cleaning for each sample during the extraction
phase, which is time consuming. The method developed by Coles

2.2

|

Chromatographic conditions and apparatus

et al. (2007) is a complicated procedure that requires the number
of drops per second passing through the solid‐phase extraction cartridge to be controlled and monitored. In the method by Wegner
et al. (2004) they used a 0.05 mL sample; however, a 30% variation
in concentration was acceptable and no LOQ, recovery, accuracy or
precision data was listed. The Guzman Sanchez‐Migallon et al.
(2014) method had a smaller sample size (0.05 mL) but used only
three replicates, not five, for validation and used a different plasma
than the actual sample for the validation process. The method
developed by Naidong et al. (2000) used normal‐phase high‐
performance liquid chromatography MS to improve sensitivity and
peak shape; however, that type of chromatography is not commonly used in many laboratories. By optimizing chromatography
conditions hydromorphone can be detected using reverse‐phase

The chromatography system consisted of a 2695 separation module
and an Acuity QDa single‐quadrupole mass detector (Waters, Milford,
MA, USA). Separation was achieved on an Atlantis T3 column
(4.6 × 150 mm, 3 μm) preceded by a 3 μm Atlantis T3 guard column.
The mobile phase was a mixture of (A) water with 0.1% formic acid
and (B) acetonitrile with 0.1% formic acid (91:9). The mixture was
pumped at a starting gradient of 91% A and 9% B and held for
4 min, and then was adjusted to 85% A and 15% B over 6 min, and
back to initial conditions over 3 min. The flow rate was 0.70 mL/min,
and the column temperature was 30°C. The compounds were
detected by positive selected ion recording. The scan rate was 2
points/s, gain 1, capillary voltage 0.6 kV, cone voltage 12, ion source
temperature 150°C and probe temperature 600°C. Nitrogen was used

chromatography.
The aim of this paper is to describe a simple, sensitive and accurate method for extracting hydromorphone from small‐volume
plasma samples. This method has been successfully applied to
bearded dragon samples analyzed at the author's institution and
should be applicable to other species. It could be useful to those
investigators dealing with small sample volumes, particularly when
conducting pharmacokinetic studies that require multiple sampling
from the same animal.

FIGURE 1

Structures for hydromorphone and naltrexone

COX
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as the nebulizing gas. Hydromorphone was detected at 286.10 m/z

with 1.0 mL of 2% formic acid in acetonitrile–methanol (40:60) and

and naltrexone was detected at 342.41 m/z.

then evaporated to dryness with nitrogen gas. Samples were
reconstituted in 250 μL of mobile phase and 60 μL injected into the
HPLC system.

2.3

|

Sample preparation

Hydromorphone was extracted from plasma samples using a solid‐
phase extraction method with Oasis HLB cartridges (Waters, Milford,

3

RESULTS AND DISCUSSION

|

MA, USA). Briefly, previously frozen plasma samples were thawed
and vortexed and 100 μL was transferred to a 13 × 100 mm glass
tube then 60 μL of internal standard (0.1 μg/mL naltrexone) was

3.1

|

Method development and optimization

added. Three hundred microliters of water–methanol (65:35) was

We wanted to develop a simple, straightforward method that would

added and tubes were vortexed and allowed to stand for 3 min, and

be effective with small volume samples. Several organic solutions and

then centrifuged for 15 min at 1020g. The supernatant was added

mixtures were tested during optimization of the extraction proce-

to a prewet Oasis 1 cm3 cartridge (1 mL methanol, 1 mL of water)

dure, including acetonitrile, methanol, trichloroacetic acid, ethyl ace-

and washed with 1 mL of 3% methanol in water. Samples were eluted

tate, hexane, and methylene chloride. All were found to produce

FIGURE 2 Chromatograms for
hydromorphone in bearded dragons. (a) A
blank bearded dragon sample; (b) a 25 ng/mL
spiked plasma standard; and (c) a plasma
sample from a bearded dragon 1 h after an
0.5 mg/kg subcutaneous dose of
hydromorphone was administered
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lower recoveries compared to the SPE technique with Oasis HLB
cartridges.
During the development of the SPE technique several different
cartridges were examined besides the Oasis HLB (Waters, Milford,

ET AL.

TABLE 1 Intra‐assay accuracy, precision and assay linearity for
hydromorphone in plasma
Intra‐assay variability
(n = 5)
Concentration
added (ng/mL)

Concentration measured Accuracy
(ng/mL) (mean ± SD)
(%)

CV
(%)

Oasis HLB cartridges, with a hydrophilic–lipophilic balanced copol-

3.5

3.5 ± 0.21

100

5.9

ymer, enabled high recoveries for both hydromorphone and

15

15 ± 0.91

100

6.1

naltrexone; all others had very low recoveries or poor peak resolu-

35

33 ± 3.08

94

9.2

tion. Once an appropriate cartridge was selected we also looked at

75

72 ± 3.56

96

5.0

various wash solution combinations, including 1, 3, 5 and 7% meth-

150

157 ± 9.13

105

5.8

anol in water. The 5 and 7% solutions caused a decrease in recov-

350

354 ± 4.1

101

1.2

ery and the 1% solution produced an eluent that when re‐dissolved

Assay linearity (n = 5)

MA, USA), including Strata‐X, Strata‐XA (Phenomenex, Torrance,
CA, USA) and Sep pak plus (Waters, Milford, MA, USA). Use of

could not be injected into the system because of particulates. The

Mean ± SD

CV (%)

3% solution was found to produce the greatest recovery with the

y‐Intercept

0.0020 ± 0.0001

5.0

best peak resolution. The elution composition was part of a stan-

Slope

0.0081 ± 0.0005

6.1

0.9992 ± 0.0002

0.02

dard protocol recommended by the manufacturer which worked
well for the plasma extraction. The amount was increased from
300 μL twice to 500 μl twice. This increased the recovery by

2

r

SD, Standard deviation; n, number of samples; CV, coefficient of variation.

roughly 15%.
TABLE 2
(n = 5)

3.2
3.2.1

Method validation

|
|

Selectivity

For specificity testing, untreated plasma from bearded dragons was
prepared in the same manner as study samples and no endogenous
components interfered with elution of the compounds of interest.
Six different blank samples were used in the pre‐validation process
and a blank sample from each animal was included in the analysis.

Inter‐assay variability for hydromorphone in plasma and

Concentration
added (ng/mL)

Concentration measured
(ng/mL) (mean ± SD)

Accuracy
(%)

CV
(%)

3.5

3.4 ± 0.17

99

5.2

15

15 ± 1.08

100

7.1

35

36 ± 1.41

103

4.0

75

74 ± 6.92

99

9.3

150

152 ± 6.49

101

4.3

350

353 ± 10.38

101

2.9

The elution chemicals were also checked for possible chromatogram
interference. Figure 2 illustrates selected ion recording chromato-

SD, Standard deviation; n, number of days; CV, coefficient of variation.

grams of (a) a blank bearded dragon sample, (b) a 25 ng/mL spiked
plasma standard and (c) a plasma sample from a bearded dragon 1 h
after

subcutaneous

administration

of

a

0.5 mg/kg

dose

of

3.2.3

|

Recovery, LLOQ

hydromorphone. The retention times in plasma for hydromorphone

The recovery (Table 3) of hydromorphone from spiked plasma was

and naltrexone were 4.60 and 10.50 min in bearded dragons, respec-

determined by comparing the extracted areas with the directly

tively. Drugs that could be used in combination with hydromorphone

injected analyte areas and ranged from 88 to 99%. The relative stan-

in treatment protocols include meloxicam, dexmedetomidine, keta-

dard deviation was <10% for all values. The recovery of the internal

mine and/or midazolam. These drugs did not interfere with the analy-

standard was 92% and its relative standard deviation was 2.1%. The

sis of hydromorphone.

use of naltrexone as an internal standard corrects for the intra‐ and
inter‐day assay variability in the assay. The LLOQ was 1 ng/mL, which
represents a peak ~5 times baseline noise. The LLOQ is more than

3.2.2

|

Linearity, accuracy and precision

adequate for use in pharmacokinetic studies. If a lower LLOQ is

The plasma peak ratio (area of hydromorphone divided by the internal
standard area) vs the concentration was plotted and produced a linear
curve for the concentration range used (1–500 ng/mL) with a correla-

TABLE 3

Recovery for hydromorphone in plasma and (n = 5)

Concentration added (ng/mL)

Recovery (%)

was y = 0.0081x + 0.0020 (Table 1) where y represents the peak area

3.5

99

ratio of hydromorphone to internal standard and x represents the

15

90

plasma concentration of hydromorphone in nanograms per milliliter.

35

90

Intra‐ and inter‐day assay coefficients of variation (CV) for plasma

75

88

spiked with specific concentrations of hydromorphone ranged from

150

93

1.2% to 9.3%. The precision was found to be well below the set

350

91

tion coefficient of 0.9992. A typical equation for the calibration curve

±15% for all quality control samples as shown in Tables 1 and 2.

n, Number of days.
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Chen, Y. L., Hanson, G. D., Jiang, X., & Naidong, W. (2002). Simultaneous
determination of hydrocodone and hydromorphone in human plasma
by liquid chromatography with tandem mass spectrometric detection.
Journal of Chromatography B, 769, 55–64.
Coles, R., Kushnir, M. M., Nelson, G. J., McMillin, G. A., & Urry, F. M.
(2007). Simultaneous determination of codeine, morphine,
hydrocodone, hydromorphone, oxycodone and 6‐acetylmorphine in
urine, serum, plasma, whole blood, and meconium. Journal of Analytical
Toxicology, 31, 1–14.
Dahn, T., Gunn, J., Kriger, S., & Terrell, A. R. (2010). Quantitation of
morphine, codeine, hydrocodone, hydromorphone, oxycodone,
oxymorphone and 6‐monoacetylmorphine (6‐MAM) in urine, blood,
serum or plasma using liquid chromatography with tandem mass
spectrometry detection. Methods in Molecular Biology, 603,
411–422.

FIGURE 3 Concentration–time profile of hydromorphone in a
bearded dragon after a 0.5 mg/kg subcutaneous dose

needed, the sample size could be increased. The lower limit of detection was 0.5 ng/mL, which represents a peak ~3 times baseline noise.

3.3

Stability

|

Testing of the short‐term stability of the quality control standards
indicated that there was a 3% loss of hydromorphone after 24 h in
the autosampler and 14% drug loss after 24 h in the refrigerator at
4°C. Therefore, if there were a power or equipment failure, samples
could be reanalyzed, especially if they were not refrigerated. Samples
in our studies were thawed once and analyzed; however, there was no
loss of drug after three freeze–thaw cycles.

4

|

C O N CL U S I O N

In conclusion, this analytical procedure was validated in terms of
recovery, linearity, LLOQ, precision and accuracy. The limit of quantification and recovery are more than adequate for use in pharmacokinetic studies. Our results indicate that this HPLC procedure is a
reproducible method that provides consistent quantification of
hydromorphone in plasma. The addition of naltrexone as an internal
standard also allows for the correction of intra‐ and inter‐assay variability. This method has been used successfully to determine
hydromorphone concentrations in plasma samples at this institution.
Figure 3 is a representative concentration–time profile from a
hydromorphone pharmacokinetic study conducted in bearded dragons
after receiving a 0.5 mg/kg subcutaneous dose of hydromorphone.
This method should be applicable to other species.
ORCID
Sherry Cox
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